首页 > 最新文献

Arab Journal of Urology最新文献

英文 中文
Comparison of ring instruments and classic circumcision methods: a systematic review and meta-analysis. 环形器械与经典包皮环切方法的比较:系统回顾和荟萃分析。
IF 1.5 Q2 Medicine Pub Date : 2022-05-23 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2071545
Yavuz Güler, Gökhun Çağdaş Özmerdiven, Akif Erbin

Aim: To determine the advantages and disadvantages of both methods by comparing classic circumcision methods with circumcision methods assisted by ring instruments.

Material-methods: Only studies that compared open procedures and ring devices for male circumcision were included. A total of 6226 patients were examined in 14 studies. The methodological quality of RCT was evaluated using Cochrane collaboration's tools. The Review Manager software statistical package was used to analyze the ORs for dichotomous variables and the mean differences for continuous variables. The proportion of heterogeneity across the studies was tested using the I 2 index. Potential publication bias was assessed by identifying the presence of visual asymmetry/symmetry with funnel plot studies.

Results: There were 1812 patients in the open circumcision group and 4414 patients in the ring groups. In total, there was no difference identified between the groups. The open procedure had an advantage compared to the Plastibell subgroup for hemorrhage, while in the other two subgroups, the ring instrument groups had the advantage. Statistically significant in favor of ring devices was found in operating time.There was no difference between the groups for early (postoperative) pain scores. For late-period pain scores, differences with statistical significance were identified in favor of ring devices both in subgroups and in total. For satisfaction, apart from one study in the PrePex group, statistical significance was obtained in favor of ring devices for the other subgroups and in total.

Conclusion: The main factors in favor of the use of ring instruments for circumcision are the short total surgical duration, not requiring advanced surgical experience, ease of learning and application, and patient relative satisfaction rates. However, it is a condition to know open circumcision methods and to have experience of this surgery for use in situations with hemorrhage complications, mainly, and without ring instruments of appropriate size.

目的:通过对经典包皮环切方法与环器辅助包皮环切方法的比较,确定两种方法的优缺点。材料方法:仅包括比较开放手术和环环装置的研究。14项研究共检查了6226例患者。RCT的方法学质量使用Cochrane协作工具进行评估。使用Review Manager软件统计软件包分析二分类变量的or和连续变量的均值差异。采用i2指数对各研究的异质性比例进行检验。通过漏斗图研究确定视觉不对称/对称的存在来评估潜在的发表偏倚。结果:开腹环切组1812例,环切组4414例。总的来说,两组之间没有发现差异。与Plastibell亚组相比,开放手术在出血方面具有优势,而在其他两个亚组中,环形器械组具有优势。在手术时间上,有统计学意义的环形装置。两组早期(术后)疼痛评分无差异。对于后期疼痛评分,无论是在亚组还是在总体上,都发现了有利于环形装置的差异具有统计学意义。对于满意度,除了PrePex组的一项研究外,其他亚组和总体上都获得了支持环装置的统计学意义。结论:环形器械在包皮环切术中使用的主要因素是手术总时间短,不需要高级手术经验,易于学习和使用,患者相对满意度高。然而,这是一个条件,了解开放包皮环切术的方法,并有这种手术的经验,用于出血并发症的情况下,主要是,没有适当大小的环器械。
{"title":"Comparison of ring instruments and classic circumcision methods: a systematic review and meta-analysis.","authors":"Yavuz Güler,&nbsp;Gökhun Çağdaş Özmerdiven,&nbsp;Akif Erbin","doi":"10.1080/2090598X.2022.2071545","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2071545","url":null,"abstract":"<p><strong>Aim: </strong>To determine the advantages and disadvantages of both methods by comparing classic circumcision methods with circumcision methods assisted by ring instruments.</p><p><strong>Material-methods: </strong>Only studies that compared open procedures and ring devices for male circumcision were included. A total of 6226 patients were examined in 14 studies. The methodological quality of RCT was evaluated using Cochrane collaboration's tools. The Review Manager software statistical package was used to analyze the ORs for dichotomous variables and the mean differences for continuous variables. The proportion of heterogeneity across the studies was tested using the I 2 index. Potential publication bias was assessed by identifying the presence of visual asymmetry/symmetry with funnel plot studies.</p><p><strong>Results: </strong>There were 1812 patients in the open circumcision group and 4414 patients in the ring groups. In total, there was no difference identified between the groups. The open procedure had an advantage compared to the Plastibell subgroup for hemorrhage, while in the other two subgroups, the ring instrument groups had the advantage. Statistically significant in favor of ring devices was found in operating time.There was no difference between the groups for early (postoperative) pain scores. For late-period pain scores, differences with statistical significance were identified in favor of ring devices both in subgroups and in total. For satisfaction, apart from one study in the PrePex group, statistical significance was obtained in favor of ring devices for the other subgroups and in total.</p><p><strong>Conclusion: </strong>The main factors in favor of the use of ring instruments for circumcision are the short total surgical duration, not requiring advanced surgical experience, ease of learning and application, and patient relative satisfaction rates. However, it is a condition to know open circumcision methods and to have experience of this surgery for use in situations with hemorrhage complications, mainly, and without ring instruments of appropriate size.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40592067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database. 淋巴结阳性非转移性膀胱癌的生存结局:国家癌症数据库的分析。
IF 1.5 Q2 Medicine Pub Date : 2022-05-20 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2077001
Amr A Elbakry, Tyler Trump, Christopher Ferari, Malcom D Mattes, Adam Luchey

Introduction: Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not been well established. Our study aims to study the trends of the reported treatment options offered to patients with cN+ bladder cancer in a national database and to evaluate the effect of various treatments, including radiation, on survival.

Methods: The National Cancer Database (NCDB) was used to identify cN+ bladder cancer patients who received chemotherapy alone or in combination with radical cystectomy (RC) or radiotherapy. 3,481 patients were included and divided into 4 groups: chemotherapy only, chemotherapy and RC, chemotherapy and radiation therapy, and chemotherapy, RC, and radiation therapy. Demographic data was compared using ANOVA for continuous variables, and Chi-square for categorical variables. Multivariable analysis was done to compare groups using a multinomial logistic regression model. Kaplan-Meier test was used for survival analysis and Cox-Regression was used for multivariable survival analysis.

Results: Patients undergoing RC were significantly younger (P <0.001). There was a significant difference between the groups regarding racial distribution, facility-type and insurance status. There was no difference in gender, CharlsonDeyo score, financial or educational status. Patients who underwent combination therapy with chemotherapy and RC were found to have the longest median survival time at 27 months. Multivariable analysis showed that final treatment, age, sex, CharlsonDeyo comorbidity score, TNM edition and facility-type were significant survival predictors. Race, insurance and financial status failed to maintain significance. There was no survival difference between the chemotherapy group and chemo-radiotherapy group.

Conclusions: The combination of surgery and chemotherapy achieves statistically significant superior survival in cN+ bladder cancer. Adding radiotherapy to chemotherapy did not improve survival in this group of patients.

Abbreviations: (cN+): Clinically node-positive non-metastatic, (MIBC): Muscle invasive bladder cancer, (NCDB): National Cancer Database, (NAC): Neoadjuvant chemotherapy, (RC): Radical Cystectomy.

临床淋巴结阳性的非转移性膀胱癌(cN+)已经成为几项研究的目标,旨在为这一人群建立一个标准的护理。有限的研究表明,各种多模式治疗方法对生存有好处。放射治疗的作用尚未得到很好的确定。我们的研究旨在研究国家数据库中cN+膀胱癌患者的治疗方案的趋势,并评估各种治疗方法(包括放疗)对生存的影响。方法:使用国家癌症数据库(NCDB)对单独化疗或联合根治性膀胱切除术(RC)或放疗的cN+膀胱癌患者进行鉴定。纳入3481例患者,分为单纯化疗组、化疗+ RC组、化疗+放疗组、化疗+ RC +放疗组。人口统计数据对连续变量采用方差分析,对分类变量采用卡方分析。采用多项逻辑回归模型进行多变量分析。生存分析采用Kaplan-Meier检验,多变量生存分析采用Cox-Regression。结论:cN+膀胱癌手术加化疗的生存率有统计学意义。在化疗的基础上加放疗并没有提高该组患者的生存率。缩写:(cN+):临床淋巴结阳性非转移性,(MIBC):肌肉浸润性膀胱癌,(NCDB):国家癌症数据库,(NAC):新辅助化疗,(RC):根治性膀胱切除术。
{"title":"Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database.","authors":"Amr A Elbakry,&nbsp;Tyler Trump,&nbsp;Christopher Ferari,&nbsp;Malcom D Mattes,&nbsp;Adam Luchey","doi":"10.1080/2090598X.2022.2077001","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2077001","url":null,"abstract":"<p><strong>Introduction: </strong>Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not been well established. Our study aims to study the trends of the reported treatment options offered to patients with cN+ bladder cancer in a national database and to evaluate the effect of various treatments, including radiation, on survival.</p><p><strong>Methods: </strong>The National Cancer Database (NCDB) was used to identify cN+ bladder cancer patients who received chemotherapy alone or in combination with radical cystectomy (RC) or radiotherapy. 3,481 patients were included and divided into 4 groups: chemotherapy only, chemotherapy and RC, chemotherapy and radiation therapy, and chemotherapy, RC, and radiation therapy. Demographic data was compared using ANOVA for continuous variables, and Chi-square for categorical variables. Multivariable analysis was done to compare groups using a multinomial logistic regression model. Kaplan-Meier test was used for survival analysis and Cox-Regression was used for multivariable survival analysis.</p><p><strong>Results: </strong>Patients undergoing RC were significantly younger (<i>P</i> <0.001). There was a significant difference between the groups regarding racial distribution, facility-type and insurance status. There was no difference in gender, CharlsonDeyo score, financial or educational status. Patients who underwent combination therapy with chemotherapy and RC were found to have the longest median survival time at 27 months. Multivariable analysis showed that final treatment, age, sex, CharlsonDeyo comorbidity score, TNM edition and facility-type were significant survival predictors. Race, insurance and financial status failed to maintain significance. There was no survival difference between the chemotherapy group and chemo-radiotherapy group.</p><p><strong>Conclusions: </strong>The combination of surgery and chemotherapy achieves statistically significant superior survival in cN+ bladder cancer. Adding radiotherapy to chemotherapy did not improve survival in this group of patients.</p><p><strong>Abbreviations: </strong>(cN+): Clinically node-positive non-metastatic, (MIBC): Muscle invasive bladder cancer, (NCDB): National Cancer Database, (NAC): Neoadjuvant chemotherapy, (RC): Radical Cystectomy.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Medicinal plants in the treatment of urinary tract malignancies during the Araboislamic period (7th- 14th century AD). 阿拉伯伊斯兰时期(公元7 - 14世纪)治疗泌尿道恶性肿瘤的药用植物。
IF 1.5 Q2 Medicine Pub Date : 2022-05-18 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2077002
Achillefs Drogosis, Charalampos Mamoulakis, Emmanuel Chrysos, Gregory Tsoucalas, Spyros N Michaleas, Marianna Karamanou

Arabic medicine, or Arab-Islamic, mainly refers to all developments achieved in the Age of Khalifs, or the Golden Age of the Arab-Islamic civilization (ca 7th-14th centuries AD). Arab scholars adopted ancient Greek medicine and soon understood the essence of the fatal disease known as cancer. They introduced various new types of cancer, distinguishing other entities like infection and proposed new methods of treatment, both surgical and non-invasive. Herbal medicine after Dioscurides and Galen bloomed in the Arabic world. Malignancy of the urinary tract was identified and a plethora of herbs were used to slow down its expansion. Moreover, herbal drugs were introduced to alleviate cancerous symptomatology. Avicenna introduced Hindiba, while known scholars like Abulcasis and Rhazes noted the benefits of garlic, onion, black seeds, pomegranate, olive oil as well as leaf and bread wheat. Arabian herbal medicine may still be beneficial in anticancer fight and mainly in the palliative medicine. It should be emphasized that almost 50% of the drugs administered today have their point of origin in the plants used in antiquity.

阿拉伯医学,或阿拉伯-伊斯兰医学,主要指在哈里发时代,或阿拉伯-伊斯兰文明的黄金时代(约公元7 -14世纪)取得的所有发展。阿拉伯学者采用古希腊医学,很快就了解了被称为癌症的致命疾病的本质。他们介绍了各种新类型的癌症,区分了感染等其他实体,并提出了新的治疗方法,包括手术和非侵入性治疗。继迪奥斯库里德斯和盖伦之后,草药在阿拉伯世界开花结果。恶性泌尿道被确定和过量的草药被用来减缓其扩张。此外,还引入了草药来缓解癌症症状。阿维森纳介绍了印地巴语,而像Abulcasis和Rhazes这样的知名学者则指出了大蒜、洋葱、黑籽、石榴、橄榄油以及叶子和面包小麦的好处。阿拉伯草药可能仍然有利于抗癌,主要是在姑息医学。应该强调的是,今天使用的药物中几乎有50%来源于古代使用的植物。
{"title":"Medicinal plants in the treatment of urinary tract malignancies during the Araboislamic period (7<sup>th</sup>- 14<sup>th</sup> century AD).","authors":"Achillefs Drogosis,&nbsp;Charalampos Mamoulakis,&nbsp;Emmanuel Chrysos,&nbsp;Gregory Tsoucalas,&nbsp;Spyros N Michaleas,&nbsp;Marianna Karamanou","doi":"10.1080/2090598X.2022.2077002","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2077002","url":null,"abstract":"<p><p>Arabic medicine, or Arab-Islamic, mainly refers to all developments achieved in the Age of Khalifs, or the Golden Age of the Arab-Islamic civilization (ca 7<sup>th</sup>-14<sup>th</sup> centuries AD). Arab scholars adopted ancient Greek medicine and soon understood the essence of the fatal disease known as cancer. They introduced various new types of cancer, distinguishing other entities like infection and proposed new methods of treatment, both surgical and non-invasive. Herbal medicine after Dioscurides and Galen bloomed in the Arabic world. Malignancy of the urinary tract was identified and a plethora of herbs were used to slow down its expansion. Moreover, herbal drugs were introduced to alleviate cancerous symptomatology. Avicenna introduced Hindiba, while known scholars like Abulcasis and Rhazes noted the benefits of garlic, onion, black seeds, pomegranate, olive oil as well as leaf and bread wheat. Arabian herbal medicine may still be beneficial in anticancer fight and mainly in the palliative medicine. It should be emphasized that almost 50% of the drugs administered today have their point of origin in the plants used in antiquity.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men - East meets West. PI-RADS v2和定量MRI对印度男性临床意义前列腺癌检测的前瞻性评价——东西方相遇。
IF 1.5 Q2 Medicine Pub Date : 2022-05-15 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2072141
Vijay Kubihal, Vikas Kundra, Vivek Lanka, Sanjay Sharma, Prasenjit Das, Rishi Nayyar, Chandan J Das

Purpose: To validate the detection of clinically significant prostate cancer (Gleason's score ≥7) by PI-RADS v2 and to assess the ability of quantitative MRI parameters to detect clinically significant prostate cancer (CSPCa) in Indian men.

Methods: Adult men (n = 95) with serum PSA >4 ng/ml were prospectively evaluated with multiparametric MRI (mpMRI) followed by histopathological evaluation using systematic 12-core prostate biopsy in 69 patients and prostatectomy specimens in 26 patients, performed within six weeks of mpMRI. The imaging and the pathology were divided into 12 sectors per prostate. For the validation of PI-RADS v2, a cut-off of PI-RADS v2 score ≥ 3 and PI-RADS v2 score ≥ 4 were compared to histopathology as a reference standard. Further, quantitative parameters, apparent diffusion coefficient (ADC), Ktrans, and Kep were correlated with the Gleason score and evaluated for their ability to distinguish between sectors with CSPCa and sectors without CSPCa.

Results: PI-RADS score ≥ 4 showed higher specificity (89%) than PI-RADS score ≥ 3 (72.2%) at the cost of mild but not significant reduction of sensitivity (sensitivity-87.6% vs 91.9), (n = 1,140 sectors, 95 patients). PI-RADS v2 and quantitative parameters demonstrated the ability to discriminate sectors positive vs negative for CSPCa: AUC (area under the curve) for ADC was 0.928, PI-RADS v2 was 0.903, Ktrans was 0.897 and Kep was 0.695. Gleason score correlated well with PI-RADS (r = 0.74), ADC (r = -0.73) and Ktrans (r = 0.69).

Conclusion: PI-RADS v2 is a reliable method for the detection and localization of clinically significant prostate cancer in Indian men, suggesting applicability beyond European or American demographics. Quantitative mpMRI parameters can detect clinically significant prostate cancer with similar test characteristics as PI-RADS v2.

目的:验证PI-RADS v2对临床显著性前列腺癌(Gleason评分≥7)的检测效果,评估MRI定量参数对印度男性临床显著性前列腺癌(CSPCa)的检测能力。方法:对血清PSA >4 ng/ml的成年男性(n = 95)进行多参数MRI (mpMRI)前瞻性评估,然后在mpMRI后6周内进行69例系统12核前列腺活检和26例前列腺切除术标本的组织病理学评估。每个前列腺的影像学和病理学分为12个扇区。为了验证PI-RADS v2,将PI-RADS v2评分≥3分和PI-RADS v2评分≥4分作为组织病理学的参考标准进行比较。此外,定量参数、表观扩散系数(ADC)、Ktrans和Kep与Gleason评分相关,并评估它们区分有CSPCa和没有CSPCa行业的能力。结果:PI-RADS评分≥4的特异性(89%)高于PI-RADS评分≥3的特异性(72.2%),但敏感性轻度但不显著降低(敏感性为87.6% vs 91.9), (n = 1,140个部门,95例患者)。PI-RADS v2和定量参数显示了区分CSPCa阳性和阴性部门的能力:ADC的AUC(曲线下面积)为0.928,PI-RADS v2为0.903,Ktrans为0.897,Kep为0.695。Gleason评分与PI-RADS (r = 0.74)、ADC (r = -0.73)、Ktrans (r = 0.69)相关。结论:PI-RADS v2是一种可靠的检测和定位印度男性临床显著前列腺癌的方法,适用于欧美以外的人群。定量mpMRI参数可以检测出具有临床意义的前列腺癌,其检测特征与PI-RADS v2相似。
{"title":"Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men - East meets West.","authors":"Vijay Kubihal,&nbsp;Vikas Kundra,&nbsp;Vivek Lanka,&nbsp;Sanjay Sharma,&nbsp;Prasenjit Das,&nbsp;Rishi Nayyar,&nbsp;Chandan J Das","doi":"10.1080/2090598X.2022.2072141","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2072141","url":null,"abstract":"<p><strong>Purpose: </strong>To validate the detection of clinically significant prostate cancer (Gleason's score ≥7) by PI-RADS v2 and to assess the ability of quantitative MRI parameters to detect clinically significant prostate cancer (CSPCa) in Indian men.</p><p><strong>Methods: </strong>Adult men (n = 95) with serum PSA >4 ng/ml were prospectively evaluated with multiparametric MRI (mpMRI) followed by histopathological evaluation using systematic 12-core prostate biopsy in 69 patients and prostatectomy specimens in 26 patients, performed within six weeks of mpMRI. The imaging and the pathology were divided into 12 sectors per prostate. For the validation of PI-RADS v2, a cut-off of PI-RADS v2 score ≥ 3 and PI-RADS v2 score ≥ 4 were compared to histopathology as a reference standard. Further, quantitative parameters, apparent diffusion coefficient (ADC), K<sup>trans</sup>, and K<sub>ep</sub> were correlated with the Gleason score and evaluated for their ability to distinguish between sectors with CSPCa and sectors without CSPCa.</p><p><strong>Results: </strong>PI-RADS score ≥ 4 showed higher specificity (89%) than PI-RADS score ≥ 3 (72.2%) at the cost of mild but not significant reduction of sensitivity (sensitivity-87.6% vs 91.9), (n = 1,140 sectors, 95 patients). PI-RADS v2 and quantitative parameters demonstrated the ability to discriminate sectors positive vs negative for CSPCa: AUC (area under the curve) for ADC was 0.928, PI-RADS v2 was 0.903, K<sup>trans</sup> was 0.897 and K<sub>ep</sub> was 0.695. Gleason score correlated well with PI-RADS (r = 0.74), ADC (r = -0.73) and K<sup>trans</sup> (r = 0.69).</p><p><strong>Conclusion: </strong>PI-RADS v2 is a reliable method for the detection and localization of clinically significant prostate cancer in Indian men, suggesting applicability beyond European or American demographics. Quantitative mpMRI parameters can detect clinically significant prostate cancer with similar test characteristics as PI-RADS v2.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40588979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naïve patients with suspicious prostate cancer. PIRADS评分系统多参数磁共振成像在naïve可疑前列腺癌活检患者中的表现。
IF 1.5 Q2 Medicine Pub Date : 2022-04-24 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2067615
Amr Nowier, Hesham Mazhar, Rasha Salah, Mohamed Shabayek

Background: Use of multi-parametric magnetic resonance imaging (mp-MRI) and Prostate Imaging Reporting and Data System (PI-RADS) scoring system allowed more precise detection of prostate cancer (PCa). Our study aimed at evaluating the diagnostic performance of mp-MRI in detection of PCa.

Methods: Eighty-six patients suspected to have prostate cancer were enrolled. All patients underwent mp-MRI followed by systematic and targeted trans-rectal ultrasound (TRUS) guided prostate biopsies. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of mp-MRI were evaluated.

Results: Forty-six patients (53.5%) had prostate cancer on targeted and systematic TRUS biopsies. On mp-MRI, 96.6% of lesions with PI-RADS < 3 revealed to be benign by TRUS biopsy, 73.3% of lesions with PI-RADS 4 showed ISUP grades ≥1, whereas all PI-RADS 5 lesions showed high ISUP grades ≥ 3. For PI-RADS 3 lesions, 62.5% of them revealed to be benign and 37.5% showed ISUP grades ≥1 by TRUS biopsy. PI-RADS scores ˃3 had 69.57% sensitivity and 85% specificity for detection of PCa. On adding the equivocal PI-RADS 3 lesions, PI-RADS scores ≥3 had higher sensitivity (97.83%), but at the cost of lower specificity (32.5%).

Conclusion: Mp-MRI using PI-RADS V2 scoring system categories ≤3 and >3 could help in detection of PCa. PI-RADS 3 lesions are equivocal. Including PI-RADS lesions ≥3 demonstrated higher sensitivity, but at the cost of lower specificity for mp-MRI in diagnosis for Pca.

Abbreviations: CDR: cancer detection rates; DRE: digital rectal examination; ISUP: international society of urological pathology; mp-MRI: multi-parametric magnetic resonance imaging; NPV: negative predictive value; PCa: prosatate cancer; PI-RADS: Prostate Imaging Reporting and Data System; PPV: Positive predictive value; PSA: prostate specific antigen; TRUS: transrectal ultrasound.

背景:使用多参数磁共振成像(mp-MRI)和前列腺成像报告和数据系统(PI-RADS)评分系统可以更精确地检测前列腺癌(PCa)。我们的研究旨在评估mp-MRI在检测前列腺癌中的诊断性能。方法:86例疑似前列腺癌患者入选。所有患者均接受mp-MRI检查,然后进行系统和定向经直肠超声(TRUS)引导的前列腺活检。评估mp-MRI的敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确性。结果:46例(53.5%)患者经靶向和系统TRUS活检发现前列腺癌。在mp-MRI上,96.6% PI-RADS < 3的病变经TRUS活检显示为良性,73.3% PI-RADS 4的病变ISUP分级≥1,而所有PI-RADS 5的病变ISUP分级均为高≥3。PI-RADS 3病变,62.5%为良性,37.5%经TRUS活检显示ISUP分级≥1。PI-RADS评分_(3)检测PCa的敏感性为69.57%,特异性为85%。当加入模棱两可的PI-RADS 3病变时,PI-RADS评分≥3的敏感性更高(97.83%),但以较低的特异性为代价(32.5%)。结论:Mp-MRI采用PI-RADS V2评分系统,分级≤3和>3有助于前列腺癌的检测。PI-RADS 3病变不明确。包括PI-RADS≥3的病变表现出更高的敏感性,但以mp-MRI诊断Pca的特异性较低为代价。缩写词:CDR:癌症检出率;DRE:直肠指检;国际泌尿病理学会;mp-MRI:多参数磁共振成像;NPV:负预测值;PCa:前列腺癌;PI-RADS:前列腺影像报告与数据系统;PPV:阳性预测值;PSA:前列腺特异性抗原;TRUS:经直肠超声。
{"title":"Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naïve patients with suspicious prostate cancer.","authors":"Amr Nowier,&nbsp;Hesham Mazhar,&nbsp;Rasha Salah,&nbsp;Mohamed Shabayek","doi":"10.1080/2090598X.2022.2067615","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2067615","url":null,"abstract":"<p><strong>Background: </strong>Use of multi-parametric magnetic resonance imaging (mp-MRI) and Prostate Imaging Reporting and Data System (PI-RADS) scoring system allowed more precise detection of prostate cancer (PCa). Our study aimed at evaluating the diagnostic performance of mp-MRI in detection of PCa.</p><p><strong>Methods: </strong>Eighty-six patients suspected to have prostate cancer were enrolled. All patients underwent mp-MRI followed by systematic and targeted trans-rectal ultrasound (TRUS) guided prostate biopsies. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of mp-MRI were evaluated.</p><p><strong>Results: </strong>Forty-six patients (53.5%) had prostate cancer on targeted and systematic TRUS biopsies. On mp-MRI, 96.6% of lesions with PI-RADS < 3 revealed to be benign by TRUS biopsy, 73.3% of lesions with PI-RADS 4 showed ISUP grades ≥1, whereas all PI-RADS 5 lesions showed high ISUP grades ≥ 3. For PI-RADS 3 lesions, 62.5% of them revealed to be benign and 37.5% showed ISUP grades ≥1 by TRUS biopsy. PI-RADS scores ˃3 had 69.57% sensitivity and 85% specificity for detection of PCa. On adding the equivocal PI-RADS 3 lesions, PI-RADS scores ≥3 had higher sensitivity (97.83%), but at the cost of lower specificity (32.5%).</p><p><strong>Conclusion: </strong>Mp-MRI using PI-RADS V2 scoring system categories ≤3 and >3 could help in detection of PCa. PI-RADS 3 lesions are equivocal. Including PI-RADS lesions ≥3 demonstrated higher sensitivity, but at the cost of lower specificity for mp-MRI in diagnosis for Pca.</p><p><strong>Abbreviations: </strong>CDR: cancer detection rates; DRE: digital rectal examination; ISUP: international society of urological pathology; mp-MRI: multi-parametric magnetic resonance imaging; NPV: negative predictive value; PCa: prosatate cancer; PI-RADS: Prostate Imaging Reporting and Data System; PPV: Positive predictive value; PSA: prostate specific antigen; TRUS: transrectal ultrasound.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40588981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The R.E.N.A.L score's relevance in determining perioperative and oncological outcomes: a Middle-Eastern tertiary care center experience. R.E.N.A.L评分在确定围手术期和肿瘤预后中的相关性:中东三级护理中心的经验。
IF 1.5 Q2 Medicine Pub Date : 2022-04-17 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2064041
Nassib Abou Heidar, Nizar Hakam, Jose M El-Asmar, Jad Najdi, Mark A Khauli, Jad Degheili, Albert El-Hajj, Rami Nasr, Wassim Wazzan, Muhammad Bulbul, Deborah Mukherji, Raja Khauli

Objective: The aim of this study is to evaluate the significance of the R.E.N.A.L nephrometry scoring system in predicting perioperative and oncological outcomes and determining the surgical approach of choice for kidney tumors.Patients and Methods: Our study retrospectively reviewed outcomes from the year 2002 to 2017. Mann-Whitney U test was used to compare continuous variables and chi-square test was used to compare categorical variables. Kaplan-Meier estimates and multivariable cox proportional hazard regression were performed to determine an association between the different R.E.N.A.L categories and disease recurrence or mortality.

Results: A total of 325 patients underwent kidney surgery The most common R.E.N.A.L score category in our cohort study was intermediate (41.2%), followed by low, (33.2%) and high (25.5%). Patients with a high R.E.N.A.L score had worse perioperative outcomes compared to those with a low R.E.N.A.L score. High R.E.N.A.L score patients were 3 times more likely to receive blood transfusions compared to those with a low R.E.N.A.L score (19.4% vs 6.3%, p = 0.018), and a statistically significant longer hospital length of stay was also observed between the two groups (median 4.5 vs 4 days, p = 0.0419). In addition, the only predictor of disease recurrence or mortality was a high R.E.N.A.L score (Hazard Ratio (HR) 3.65, 95% Confidence Interval (CI) 1.05-12.7, p = 0.041).

Conclusion: Our study sheds light on the use of R.E.N.A.L nephrometry score in predicting perioperative, postoperative, and oncological outcomes. Such findings may play a role in optimizing surgical approaches and pre-operative patient counseling.

目的:本研究的目的是评估R.E.N.A.L肾测量评分系统在预测围手术期和肿瘤预后以及确定肾肿瘤手术入路选择方面的意义。患者和方法:我们的研究回顾性回顾了2002年至2017年的结果。连续变量比较采用Mann-Whitney U检验,分类变量比较采用卡方检验。采用Kaplan-Meier估计和多变量cox比例风险回归来确定不同R.E.N.A.L类别与疾病复发或死亡率之间的关系。结果:共有325例患者接受了肾脏手术。在我们的队列研究中,最常见的R.E.N.A.L评分类别是中等(41.2%),其次是低(33.2%)和高(25.5%)。与低R.E.N.A.L评分的患者相比,高R.E.N.A.L评分的患者围手术期预后更差。高R.E.N.A.L评分患者接受输血的可能性是低R.E.N.A.L评分患者的3倍(19.4% vs 6.3%, p = 0.018),两组患者住院时间更长(中位数4.5 vs 4天,p = 0.0419)。此外,疾病复发或死亡的唯一预测因子是较高的R.E.N.A.L评分(风险比(HR) 3.65, 95%可信区间(CI) 1.05-12.7, p = 0.041)。结论:我们的研究阐明了R.E.N.A.L肾测量评分在预测围手术期、术后和肿瘤预后方面的应用。这些发现可能在优化手术入路和术前患者咨询方面发挥作用。
{"title":"The R.E.N.A.L score's relevance in determining perioperative and oncological outcomes: a Middle-Eastern tertiary care center experience.","authors":"Nassib Abou Heidar,&nbsp;Nizar Hakam,&nbsp;Jose M El-Asmar,&nbsp;Jad Najdi,&nbsp;Mark A Khauli,&nbsp;Jad Degheili,&nbsp;Albert El-Hajj,&nbsp;Rami Nasr,&nbsp;Wassim Wazzan,&nbsp;Muhammad Bulbul,&nbsp;Deborah Mukherji,&nbsp;Raja Khauli","doi":"10.1080/2090598X.2022.2064041","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2064041","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to evaluate the significance of the R.E.N.A.L nephrometry scoring system in predicting perioperative and oncological outcomes and determining the surgical approach of choice for kidney tumors.Patients and Methods: Our study retrospectively reviewed outcomes from the year 2002 to 2017. Mann-Whitney U test was used to compare continuous variables and chi-square test was used to compare categorical variables. Kaplan-Meier estimates and multivariable cox proportional hazard regression were performed to determine an association between the different R.E.N.A.L categories and disease recurrence or mortality.</p><p><strong>Results: </strong>A total of 325 patients underwent kidney surgery The most common R.E.N.A.L score category in our cohort study was intermediate (41.2%), followed by low, (33.2%) and high (25.5%). Patients with a high R.E.N.A.L score had worse perioperative outcomes compared to those with a low R.E.N.A.L score. High R.E.N.A.L score patients were 3 times more likely to receive blood transfusions compared to those with a low R.E.N.A.L score (19.4% vs 6.3%, p = 0.018), and a statistically significant longer hospital length of stay was also observed between the two groups (median 4.5 vs 4 days, p = 0.0419). In addition, the only predictor of disease recurrence or mortality was a high R.E.N.A.L score (Hazard Ratio (HR) 3.65, 95% Confidence Interval (CI) 1.05-12.7, p = 0.041).</p><p><strong>Conclusion: </strong>Our study sheds light on the use of R.E.N.A.L nephrometry score in predicting perioperative, postoperative, and oncological outcomes. Such findings may play a role in optimizing surgical approaches and pre-operative patient counseling.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40592065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Does immunohistochemical staining of P53, Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival? P53、Ki 67 和细胞周期蛋白 A 的免疫组化染色能准确预测 Wilms 肿瘤的复发和生存率吗?
IF 1.3 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-04-11 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2058240
Ahmed M Atwa, Ashraf T Hafez, Mohamed Abdelhameed, Mohamed Dawaba, Adel Nabeeh, Tamer E Helmy

Objective: To evaluate whether p53, cyclin A and ki67 immunohistochemical (IHC) assay can be used as predictors for Wilms' tumor (WT) unfavorable outcomes.

Methods: It is a non-concurrent cohort study including patients who underwent nephrectomy for WT from January 2000 to December 2015 in a tertiary referral center. Over a 5- year follow-up, unfavorable events, including relapse and cancer-specific mortality (CSM), were recorded. P53, cyclin A, and ki67 IHC assay were carried out for formalin-fixed paraffin-embedded WT samples.

Results: After excluding those who did not meet the inclusion criteria, 75 patients were enrolled. Of the patients, 15/75 (20%) experienced WT relapse while 11/75 (14.6%) died of WT over five years. Unfavorable histology (UFH), including prominent blastemal components and anaplasia, was found in 15/75 (20%) children.Cyclin A immunopositivity was associated with high rates of relapse and CSM. P53 and ki67 positive IHC assay did not show any statistically significant association with unfavorable outcomes. Other risk factors e.g. advanced staging, UFH, extracapsular extension, tumor rupture, lymphadenopathy, and venous thrombosis were not associated with poor prognosis. However, the presence of residual tumors was accompanied by lower survival rates.

Conclusion: Cyclin A IHC assay can be used as a predictor of WT recurrence and CSM. Further studies with prospective patterns and a larger sample size are needed.Abbreviations: WT: Wilms' tumor, UFH: unfavorable histology, IHC: immunohistochemical, PI: proliferation index, RFS: relapse-free survival, CSS: cancer-specific survival, FH: favorable histology, CSM: cancer-specific mortality, CDK: cyclin-dependent kinase.

目的评估p53、细胞周期蛋白A和ki67免疫组化(IHC)检测是否可作为预测Wilms's肿瘤(WT)不良预后的指标:这是一项非同期队列研究,包括2000年1月至2015年12月在一家三级转诊中心接受WT肾切除术的患者。在为期5年的随访中,记录了包括复发和癌症特异性死亡率(CSM)在内的不利事件。对福尔马林固定石蜡包埋的WT样本进行了P53、细胞周期蛋白A和ki67 IHC检测:结果:在排除不符合纳入标准的患者后,共纳入 75 例患者。其中,15/75(20%)例患者WT复发,11/75(14.6%)例患者在五年内死于WT。15/75(20%)名患儿中发现了不利组织学(UFH),包括突出的胚泡成分和无细胞增生。P53 和 ki67 阳性 IHC 检测与不良预后无统计学意义。其他风险因素,如晚期分期、UFH、囊外扩展、肿瘤破裂、淋巴结病和静脉血栓等,与不良预后无关。然而,存在残余肿瘤的患者生存率较低:结论:细胞周期蛋白 A IHC 检测可作为 WT 复发和 CSM 的预测指标。结论:细胞周期蛋白 A IHC 检测可作为 WT 复发和 CSM 的预测指标,需要进一步开展具有前瞻性模式和更大样本量的研究:缩写:WT:Wilms'tumor(威尔瘤);UFH:unfavorable histology(不利组织学);IHC:immunohistochemical(免疫组化);PI:proliferation index(增殖指数);RFS:relapse-free survival(无复发生存率);CSS:cancer-specific survival(癌症特异性生存率);FH:filourable histology(有利组织学);CSM:cancer-specific mortality(癌症特异性死亡率);CDK:cyclin-dependent kinase(细胞周期蛋白依赖性激酶)。
{"title":"Does immunohistochemical staining of P53, Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?","authors":"Ahmed M Atwa, Ashraf T Hafez, Mohamed Abdelhameed, Mohamed Dawaba, Adel Nabeeh, Tamer E Helmy","doi":"10.1080/2090598X.2022.2058240","DOIUrl":"10.1080/2090598X.2022.2058240","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether p53, cyclin A and ki67 immunohistochemical (IHC) assay can be used as predictors for Wilms' tumor (WT) unfavorable outcomes.</p><p><strong>Methods: </strong>It is a non-concurrent cohort study including patients who underwent nephrectomy for WT from January 2000 to December 2015 in a tertiary referral center. Over a 5- year follow-up, unfavorable events, including relapse and cancer-specific mortality (CSM), were recorded. P53, cyclin A, and ki67 IHC assay were carried out for formalin-fixed paraffin-embedded WT samples.</p><p><strong>Results: </strong>After excluding those who did not meet the inclusion criteria, 75 patients were enrolled. Of the patients, 15/75 (20%) experienced WT relapse while 11/75 (14.6%) died of WT over five years. Unfavorable histology (UFH), including prominent blastemal components and anaplasia, was found in 15/75 (20%) children.Cyclin A immunopositivity was associated with high rates of relapse and CSM. P53 and ki67 positive IHC assay did not show any statistically significant association with unfavorable outcomes. Other risk factors e.g. advanced staging, UFH, extracapsular extension, tumor rupture, lymphadenopathy, and venous thrombosis were not associated with poor prognosis. However, the presence of residual tumors was accompanied by lower survival rates.</p><p><strong>Conclusion: </strong>Cyclin A IHC assay can be used as a predictor of WT recurrence and CSM. Further studies with prospective patterns and a larger sample size are needed.<b>Abbreviations:</b> WT: Wilms' tumor, UFH: unfavorable histology, IHC: immunohistochemical, PI: proliferation index, RFS: relapse-free survival, CSS: cancer-specific survival, FH: favorable histology, CSM: cancer-specific mortality, CDK: cyclin-dependent kinase.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40592066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author self-citations in the urology literature. 泌尿外科文献中的作者自我引用。
IF 1.5 Q2 Medicine Pub Date : 2022-03-30 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2056976
Vaibhav Aggarwal

Objective: We aimed to determine the diachronous self-citation rate and the various article characteristics which can influence the rate and percentage of diachronous author self-citations using papers published in high-rank urology journals.

Methods: We included all papers (N = 327 articles) published between January 2015 to April 2015 in the European Urology, The Journal of Urology and the BJU International. We determined author self-citations using the Scopus database and used negative binomial regression to determine which article characteristics affect self-citations.

Results: 262 articles (80.2%) contained at least one self-citation.The mean number and percentage of author self-citations were 6.5 and 14.2 respectively. Adjusted analysis showed that the experimental/animal study design and the number of authors were significantly associated with both the number (IRR = 2.12, P = 0.011; IRR = 1.03, P = 0.002) and percentage of author self-citations (IRR = 2.95, P = 0.003; IRR = 1.03, P = 0.012). The number of citations in the Scopus and publication in European Urology were significantly associated with only the number of author self-citations.

Conclusion: Diachronous author self-citation rate in urology is higher compared to general medical literature but similar to other surgical subspecialties. It may depend on the study design and the number of authors in the paper. For a more comprehensive evaluation, future studies should look at the context in which self-citations were made.

目的:研究泌尿外科高水平期刊论文作者的非时性自引率及影响作者非时性自引率和百分比的文献特征。方法:纳入2015年1月至2015年4月在欧洲泌尿外科、泌尿外科杂志和BJU国际杂志上发表的所有论文(N = 327篇)。我们使用Scopus数据库来确定作者的自引,并使用负二项回归来确定哪些文章特征会影响自引。结果:262篇(80.2%)文献至少包含1条自引。作者平均自引次数为6.5次,自引百分比为14.2次。调整后的分析显示,实验/动物研究设计和作者数量与数量显著相关(IRR = 2.12, P = 0.011;IRR = 1.03, P = 0.002)和作者自引用百分比(IRR = 2.95, P = 0.003;Irr = 1.03, p = 0.012)。Scopus和《European Urology》的被引次数仅与作者自引次数显著相关。结论:泌尿外科非时性作者自引率高于普通医学文献,但与其他外科亚专科相似。这可能取决于研究设计和论文作者的数量。为了进行更全面的评价,未来的研究应该着眼于自我引用的背景。
{"title":"Author self-citations in the urology literature.","authors":"Vaibhav Aggarwal","doi":"10.1080/2090598X.2022.2056976","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2056976","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to determine the diachronous self-citation rate and the various article characteristics which can influence the rate and percentage of diachronous author self-citations using papers published in high-rank urology journals.</p><p><strong>Methods: </strong>We included all papers (N = 327 articles) published between January 2015 to April 2015 in the European Urology, The Journal of Urology and the BJU International. We determined author self-citations using the Scopus database and used negative binomial regression to determine which article characteristics affect self-citations.</p><p><strong>Results: </strong>262 articles (80.2%) contained at least one self-citation.The mean number and percentage of author self-citations were 6.5 and 14.2 respectively. Adjusted analysis showed that the experimental/animal study design and the number of authors were significantly associated with both the number (IRR = 2.12, P = 0.011; IRR = 1.03, P = 0.002) and percentage of author self-citations (IRR = 2.95, P = 0.003; IRR = 1.03, P = 0.012). The number of citations in the Scopus and publication in European Urology were significantly associated with only the number of author self-citations.</p><p><strong>Conclusion: </strong>Diachronous author self-citation rate in urology is higher compared to general medical literature but similar to other surgical subspecialties. It may depend on the study design and the number of authors in the paper. For a more comprehensive evaluation, future studies should look at the context in which self-citations were made.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40588977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis 放疗与根治性前列腺切除术作为高危局部前列腺癌患者一线决定性治疗的比较:最新的系统综述和荟萃分析
IF 1.5 Q2 Medicine Pub Date : 2022-03-30 DOI: 10.1080/2090598X.2022.2026010
A. Aydh, R. Motlagh, M. Abufaraj, K. Mori, S. Katayama, N. Grossmann, Pawel Rajawa, H. Mostafai, E. Laukhtina, B. Pradère, F. Quhal, V. Schuettfort, A. Briganti, P. Karakiewicz, Haron Fajkovic, S. Shariat
ABSTRACT Objective To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa). Methods We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS). Results A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16–1.65; and HR 1.55, 95% CI 1.25–1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76–1.34) and CSS (HR 0.69, 95% CI 0.45–1.06) between EBRT plus BT compared to RP. Conclusion While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa. Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy
【摘要】目的更新现有文献,比较外束放射治疗(EBRT)加或不加近距离放疗(BT)与根治性前列腺切除术(RP)对高危局限性前列腺癌(PCa)患者的治疗效果。方法我们对文献进行了系统回顾和荟萃分析,以评估高风险PCa患者接受EBRT合并或不合并BT与RP作为一线治疗的生存结果。我们在2021年1月查询了PubMed和Web of Science数据库。此外,在I2统计量存在或不存在异质性时,我们分别使用随机或固定效应元分析模型。我们对总生存期(OS)和癌症特异性生存期(CSS)进行了六项荟萃分析。结果共纳入27项研究,其中23项研究同时符合OS和CSS标准。与RP相比,单独EBRT的OS和CSS明显更差(风险比[HR] 1.38, 95%可信区间[CI] 1.16-1.65;HR 1.55, 95% CI 1.25-1.93)。然而,与RP相比,EBRT + BT在OS (HR 1.1, 95% CI 0.76-1.34)和CSS (HR 0.69, 95% CI 0.45-1.06)方面没有差异。结论在高危PCa患者中,单纯EBRT对肿瘤的控制效果似乎不如RP,但BT加药EBRT与RP效果无明显差异。这些数据支持除了EBRT外,还需要BT作为高风险PCa多模式RT的一部分。ADT:雄激素剥夺疗法;英国电信:近距离放射疗法;CSS:癌症特异性生存;HR:风险比;MFS:无转移生存期;MOOSE:流行病学观察性研究的meta分析;OR:优势比;OS:总生存期;PCa:前列腺癌;RR:相对风险;RP:根治性前列腺切除术;RCT:随机对照试验;(EB)RT:(外束)放射治疗
{"title":"Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis","authors":"A. Aydh, R. Motlagh, M. Abufaraj, K. Mori, S. Katayama, N. Grossmann, Pawel Rajawa, H. Mostafai, E. Laukhtina, B. Pradère, F. Quhal, V. Schuettfort, A. Briganti, P. Karakiewicz, Haron Fajkovic, S. Shariat","doi":"10.1080/2090598X.2022.2026010","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2026010","url":null,"abstract":"ABSTRACT Objective To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa). Methods We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS). Results A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16–1.65; and HR 1.55, 95% CI 1.25–1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76–1.34) and CSS (HR 0.69, 95% CI 0.45–1.06) between EBRT plus BT compared to RP. Conclusion While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa. Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60071462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis 使用扩展前列腺癌症指数综合调查进行积极监测的癌症前列腺患者的健康相关生活质量:系统回顾和荟萃分析
IF 1.5 Q2 Medicine Pub Date : 2022-02-27 DOI: 10.1080/2090598X.2021.2024368
Ahmed Abdelhafez, Khaled Hosny, A. El-Nahas, M. Liew
ABSTRACT Objective To examine the health-related quality of life (HRQoL) of patients with prostate cancer managed with active surveillance (AS) compared with those who receive definitive treatment using the Expanded Prostate Cancer Index Composite (EPIC) Survey. Methods We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and searched PubMed and ScienceDirect for articles published between April 2010 and April 2020. Eligible studies reported original data on the HRQoL of men undergoing AS for prostate cancer, including studies comparing AS to curative methods particularly radical prostatectomy, radiotherapy, and brachytherapy. Results We identified nine eligible articles, all were non-experimental observational studies of which seven were longitudinal and two were cross-sectional studies. The EPIC questionnaire was the main instrument used in all studies to assess the HRQoL. AS was noted to show the highest calculated mean score among management groups in all comparative studies at study endpoints including cross-sectional studies (95% confidence interval 2.17–5.75, P < 0.001). The maximum score deterioration for patients who were managed with AS in all studies was only 7.5 points (12.2%) after 2 years follow-up. AS had the least mean score decline among all management groups. Patients with a normal testosterone level were found to have high HRQoL scores. The number of prostate biopsies did not correlate with the HRQoL score. Conclusion Patients with prostate cancer managed with AS report less impacts on their HRQoL compared to patients who receive definitive treatments. However, further high-quality research with long-term data are required to help both the patient and the physician in making a well-informed management decision.
目的比较采用主动监测(AS)的前列腺癌患者与接受明确治疗的前列腺癌患者的健康相关生活质量(HRQoL),采用扩展前列腺癌指数综合调查(EPIC)。方法采用系统评价和荟萃分析首选报告项目(PRISMA)指南,检索PubMed和ScienceDirect 2010年4月至2020年4月间发表的文章。符合条件的研究报告了接受AS治疗前列腺癌男性HRQoL的原始数据,包括将AS与治疗方法,特别是根治性前列腺切除术、放疗和近距离放疗进行比较的研究。结果我们确定了9篇符合条件的文章,均为非实验观察性研究,其中7篇为纵向研究,2篇为横断面研究。EPIC问卷是所有研究中评估HRQoL的主要工具。值得注意的是,在包括横断面研究在内的所有比较研究终点,AS显示管理组的计算平均得分最高(95%置信区间2.17-5.75,P < 0.001)。在所有研究中,接受AS治疗的患者在2年随访后的最大评分下降仅为7.5分(12.2%)。在所有管理组中,AS组的平均得分下降幅度最小。睾酮水平正常的患者HRQoL评分较高。前列腺活检次数与HRQoL评分无相关性。结论:与接受明确治疗的患者相比,接受AS治疗的前列腺癌患者的HRQoL受到的影响较小。然而,需要进一步高质量的长期数据研究,以帮助患者和医生做出明智的管理决策。
{"title":"The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis","authors":"Ahmed Abdelhafez, Khaled Hosny, A. El-Nahas, M. Liew","doi":"10.1080/2090598X.2021.2024368","DOIUrl":"https://doi.org/10.1080/2090598X.2021.2024368","url":null,"abstract":"ABSTRACT Objective To examine the health-related quality of life (HRQoL) of patients with prostate cancer managed with active surveillance (AS) compared with those who receive definitive treatment using the Expanded Prostate Cancer Index Composite (EPIC) Survey. Methods We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and searched PubMed and ScienceDirect for articles published between April 2010 and April 2020. Eligible studies reported original data on the HRQoL of men undergoing AS for prostate cancer, including studies comparing AS to curative methods particularly radical prostatectomy, radiotherapy, and brachytherapy. Results We identified nine eligible articles, all were non-experimental observational studies of which seven were longitudinal and two were cross-sectional studies. The EPIC questionnaire was the main instrument used in all studies to assess the HRQoL. AS was noted to show the highest calculated mean score among management groups in all comparative studies at study endpoints including cross-sectional studies (95% confidence interval 2.17–5.75, P < 0.001). The maximum score deterioration for patients who were managed with AS in all studies was only 7.5 points (12.2%) after 2 years follow-up. AS had the least mean score decline among all management groups. Patients with a normal testosterone level were found to have high HRQoL scores. The number of prostate biopsies did not correlate with the HRQoL score. Conclusion Patients with prostate cancer managed with AS report less impacts on their HRQoL compared to patients who receive definitive treatments. However, further high-quality research with long-term data are required to help both the patient and the physician in making a well-informed management decision.","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42679481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arab Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1